Skip to main content

DEA Extends Telemedicine for Prescribing Controlled Meds as Pandemic Measures End

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

WEDNESDAY, May 10, 2023 – The U.S. Drug Enforcement Administration on Wednesday issued a six-month extension for people seeking to fill controlled medication prescriptions via telehealth.

That ability had been set to expire along with the ending of the pandemic public health emergency on May 11.

“These medications, including those used to treat opioid use disorder, are a vital form of care for millions of Americans who have come to rely on safe and effective telemedicine appointments,” Dr. Bobby Mukkamala, chair of the American Medical Association’s Substance Use and Pain Care Task Force, said in a statement.

“Patients being treated with these medications often have challenges securing and traveling to in-person appointments. We are grateful the DEA is approaching this issue with the gravity it deserves, and we look forward to reviewing the details of the policy when they become available,” Mukkamala added.

Prior to the pandemic, patients had to see a doctor for at least one in-person appointment before being able to access prescriptions for a long list of medications, including stimulants for attention deficit hyperactivity disorder, benzodiazepines for anxiety, and medications for opioid use disorder, sleep or pain.

The DEA had offered proposals on March 1 that would allow prescribers to prescribe one 30-day supply of these controlled medications or the opioid use disorder buprenorphine without an in-person exam. Then an exam would be required before the next prescription.

In the public comment period ending in March, the DEA received 38,000 messages about the proposals, CNN reported.

The extension through Nov. 11, 2023 gives the DEA and the U.S. Department of Health and Human Services the chance to consider the revisions and the public comments.

.“We take those comments seriously and are considering them carefully,” DEA Administrator Anne Milgram said in an agency news release. “We recognize the importance of telemedicine in providing Americans with access to needed medications, and we have decided to extend the current flexibilities for six months while we work to find a way forward to give Americans that access with appropriate safeguards.”

The extension also allows that “if a patient and a practitioner have established a telemedicine relationship on or before November 11, 2023, the same telemedicine flexibilities that governed the relationship to that point are permitted until November 11, 2024," according to the DEA.

That will hold true unless there are new rules in place by then contradicting that, CNN reported.

Sources

  • U.S. Drug Enforcement Administration, news release, May 10, 2023
  • CNN

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2023

Further Support and Information on COVID-19

Read this next

Biden Administration Could Reclassify Marijuana as Less Risky Drug

WEDNESDAY, May 1, 2024 -- The Justice Department has recommended that marijuana be reclassified as a less dangerous drug, a move that signals a significant shift in U.S. drug...

Climate Change Could Be Good News for Viruses Like COVID

MONDAY, April 29, 2024 -- Climate change -- and closed windows -- could be aiding the spread of airborne viruses like the one that causes COVID-19, a new study...

Drug, Alcohol Abuse Goes Untreated in Many Ex-Prisoners

THURSDAY, April 25, 2024 -- Most ex-cons are unlikely to receive substance use treatment following their release from prison, even though odds are high they are struggling with...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.